Scholarlink

Background and methods <p>Fractional exhaled nitric oxide (FeNO) is an important biomarker of asthma. Daily FeNO monitoring can provide longitudinal data better reflecting the variable nature of asthmatic inflammation versus single-point data. We studied adherence to daily home-based FeNO monitoring, and user experience with the Vivatmo <i>me </i>device and <i>app</i> in asthma patients in a multicentre, 12-week observational study. Adherence to daily FeNO was measured by percentage days covered (PDC) and proportion of adherent patients over time. Patients’ and physicians’ expectations were recorded by questionnaires at study entry, item-specific and global expectation fulfillment and net promoter categories scores at study end. Device usability was measured by User Experience Questionnaire (UEQ+) scores. FeNO values did not trigger direct management decisions. </p> Results <p>We enrolled n=85 asthma patients (n=23 GINA Step 1; n=37 Step 2-3; n=25 Step 4-5). Adherence to daily FeNO was high with a median PDC of 93.4% (Q1-Q3: 75-97.6%) and 68.2% of subjects covering &gt;80% of measurements. PDC was highest (p=0.04) in asthma patients aged &gt;60 years (median 99%; Q1-Q3: 87-100%) versus 40-60 years (92%; Q1-Q3: 75-98%), and 18-40 years (93%; Q1-Q3: 60-99). Item-specific expectation fulfillment was highest for “to have more safety and predictability in dealing with my asthma” (42% of patients) and “to conclude whether the therapy is suitable for the patient” (76% of physicians), and was related to asthma control. Overall, 49% of patients’, and 87% of physicians’ global expectations towards home monitoring were “fulfilled” or “absolutely fulfilled”. Usability impression was excellent (median UEQ+ score 2.05; Q1-Q3: 1.15-2.65), and handling scores were positively correlated with adherence and promoter categories.</p> Conclusions <p>Daily FeNO measurements with a home-based device (Vivatmo <i>me</i>) are feasible and well accepted. Adherence over 12 weeks, global expectation fulfillment, and device usability were highly promising, underlining the potential of home-based FeNO to support asthma management.</p> Trial registration <p>German Clinical Trial Register (DRKS) DRKS00029118, registered JUL 1<sup>st</sup>, 2022.</p> Prior presentation of results <p>Parts of the results of the study have been presented in abstract form at the European Respiratory Society (ERS) Annual Congress on SEP 8<sup>th</sup>, 2025 in Vienna, Austria. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Device adherence and user experience with daily home-based FeNO monitoring (Vivatmo me) in asthma patients: the FeNO@home observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月21日

查看全文
  • Kai M. Beeh,
  • Enrico Heffler,
  • Hartmut Timmermann,
  • Stephan Weber,
  • Antonia Schneider,
  • Sandra Wegner

摘要

Background and methods

Fractional exhaled nitric oxide (FeNO) is an important biomarker of asthma. Daily FeNO monitoring can provide longitudinal data better reflecting the variable nature of asthmatic inflammation versus single-point data. We studied adherence to daily home-based FeNO monitoring, and user experience with the Vivatmo me device and app in asthma patients in a multicentre, 12-week observational study. Adherence to daily FeNO was measured by percentage days covered (PDC) and proportion of adherent patients over time. Patients’ and physicians’ expectations were recorded by questionnaires at study entry, item-specific and global expectation fulfillment and net promoter categories scores at study end. Device usability was measured by User Experience Questionnaire (UEQ+) scores. FeNO values did not trigger direct management decisions.

Results

We enrolled n=85 asthma patients (n=23 GINA Step 1; n=37 Step 2-3; n=25 Step 4-5). Adherence to daily FeNO was high with a median PDC of 93.4% (Q1-Q3: 75-97.6%) and 68.2% of subjects covering >80% of measurements. PDC was highest (p=0.04) in asthma patients aged >60 years (median 99%; Q1-Q3: 87-100%) versus 40-60 years (92%; Q1-Q3: 75-98%), and 18-40 years (93%; Q1-Q3: 60-99). Item-specific expectation fulfillment was highest for “to have more safety and predictability in dealing with my asthma” (42% of patients) and “to conclude whether the therapy is suitable for the patient” (76% of physicians), and was related to asthma control. Overall, 49% of patients’, and 87% of physicians’ global expectations towards home monitoring were “fulfilled” or “absolutely fulfilled”. Usability impression was excellent (median UEQ+ score 2.05; Q1-Q3: 1.15-2.65), and handling scores were positively correlated with adherence and promoter categories.

Conclusions

Daily FeNO measurements with a home-based device (Vivatmo me) are feasible and well accepted. Adherence over 12 weeks, global expectation fulfillment, and device usability were highly promising, underlining the potential of home-based FeNO to support asthma management.

Trial registration

German Clinical Trial Register (DRKS) DRKS00029118, registered JUL 1st, 2022.

Prior presentation of results

Parts of the results of the study have been presented in abstract form at the European Respiratory Society (ERS) Annual Congress on SEP 8th, 2025 in Vienna, Austria.